5% Off
Irinox20 mg/ml
Beacon Pharmaceuticals PLC
৳1900.00
Add to cart
Campto20 mg/ml
IV Infusion
By
Best PriceTk /
1
Alternatives
Price
Medicine overview
Indications of Campto 20 mg/ml
Irinotecan Injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum.Irinotecan is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
Theropeutic Class
Cytotoxic Chemotherapy
Pharmacology
Irinotecan inhibits the action of topoisomerase I.
Absorption
Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex.
Distribution
The formation of this ternary complex interferes with the moving replication fork, which induces replication arrest and lethal double-stranded breaks in DNA.
Metabolism
As a result, DNA damage is not efficiently repaired and apoptosis (programmed cell death) occurs.
Dosage & Administration of Campto 20 mg/ml
Notes:Administer as a 90-minute intravenous infusion followed by LV and 5-FU. A reduction in the starting dose by one dose level may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels
Refractory colorectal malignancies
Dosage:125 mg/m2 once wkly for 4 wk, followed by a 2 wk rest period
Metastatic colorectal cancer
Dosage:As 1st line treatment: 125 mg/m2 on days 1,8,15 and 22 of a 6-wk cycle
| Condition | Dosage | Notes |
|---|---|---|
| Administer as a 90-minute intravenous infusion followed by LV and 5-FU. A reduction in the starting dose by one dose level may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels | ||
| Refractory colorectal malignancies | 125 mg/m2 once wkly for 4 wk, followed by a 2 wk rest period | |
| Metastatic colorectal cancer | As 1st line treatment: 125 mg/m2 on days 1,8,15 and 22 of a 6-wk cycle |
Dosage of Campto 20 mg/ml
Notes:Administer as a 90-minute intravenous infusion followed by LV and 5-FU. A reduction in the starting dose by one dose level may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels
Refractory colorectal malignancies
Dosage:125 mg/m2 once wkly for 4 wk, followed by a 2 wk rest period
Metastatic colorectal cancer
Dosage:As 1st line treatment: 125 mg/m2 on days 1,8,15 and 22 of a 6-wk cycle
| Condition | Dosage | Notes |
|---|---|---|
| Administer as a 90-minute intravenous infusion followed by LV and 5-FU. A reduction in the starting dose by one dose level may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels | ||
| Refractory colorectal malignancies | 125 mg/m2 once wkly for 4 wk, followed by a 2 wk rest period | |
| Metastatic colorectal cancer | As 1st line treatment: 125 mg/m2 on days 1,8,15 and 22 of a 6-wk cycle |
Interaction of Campto 20 mg/ml
Diuretics increase risks of dehydration secondary to vomiting/diarrhoea; prophylactic dexamethasone as an antiemetic may enhance lymphocytopenia; prochlorperazine may increase incidence of akathisia; antineoplastic agents (myelosuppression and diarrhoea). St John's wort, ketoconazole may reduce irinotecan exposure.
Contraindications
Patients with a known hypersensitivity to the drug or its excitements.
Side Effects of Campto 20 mg/ml
Anemia, Leukopenia, Neutropenia,Thrombocytopenia, Elevated bilirubin, Diarrhea, Nausea, Asthenia, Abdominal pain, Vomiting , Alopecia, Fever, Constipation, Anorexia, Mucositis, Pain, Dyspnea, Cough, Dizziness, Infection, Rash, Abdominal fullness, AST increased , Dyspepsia, Edema, Ascites/jaundice, Vasodilation, Thromboembolism, Hypotension, Neutropenic fever, Headache, Insomnia, Orthostatic hypotension
Pregnancy & Lactation
Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Precautions & Warnings
Early diarrhea is usually transient and infrequently severe. It may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Bradycardia may also occur.Late diarrhea can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or sepsis.Late diarrhea can be complicated by colitis, ulceration, bleeding, ileus, obstruction, and infection. Cases of megacolon and intestinal perforation have been reported.
Storage Conditions
Store at controlled room temperature 15° to 30°C. Protect from light. Keep the vial in the carton until the time of use.
Drug Classes
Cytotoxic Chemotherapy
Mode Of Action
Irinotecan inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex. The formation of this ternary complex interferes with the moving replication fork, which induces replication arrest and lethal double-stranded breaks in DNA. As a result, DNA damage is not efficiently repaired and apoptosis (programmed cell death) occurs.
Pregnancy
Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Frequently Asked Questions
What is Campto 20 mg/ml used for?
Irinotecan Injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum.Irinotecan is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
What is the dosage of Campto 20 mg/ml?
Administer as a 90-minute intravenous infusion followed by LV and 5-FU. A reduction in the starting dose by one dose level may be considered for patients with any of the following conditions: prior pelvic/abdominal radiotherapy, performance status of 2, or increased bilirubin levels.Refractory colorectal malignancies: 125 mg/m2 once wkly for 4 wk, followed by a 2 wk rest period. Metastatic colorec…
What are the side effects of Campto 20 mg/ml?
Anemia, Leukopenia, Neutropenia,Thrombocytopenia, Elevated bilirubin, Diarrhea, Nausea, Asthenia, Abdominal pain, Vomiting , Alopecia, Fever, Constipation, Anorexia, Mucositis, Pain, Dyspnea, Cough, Dizziness, Infection, Rash, Abdominal fullness, AST increased , Dyspepsia, Edema, Ascites/jaundice, Vasodilation, Thromboembolism, Hypotension, Neutropenic fever, Headache, Insomnia, Orthostatic hypote…
Who should not take Campto 20 mg/ml?
Patients with a known hypersensitivity to the drug or its excitements.
What precautions should be taken with Campto 20 mg/ml?
Early diarrhea is usually transient and infrequently severe. It may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. Bradycardia may also occur.Late diarrhea can be life threatening since it may be prolonged and may lead to dehydration, electrolyte imbalance, or s…
Is Campto 20 mg/ml safe during pregnancy and breastfeeding?
Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Disclaimer
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.